Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind study on the benefit of spironolactone for treating acne in adult women
2017-001392-22Phase 3Terminated
- Sponsor
- CHU de Nantes
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of spironolactone in acne vulgaris (2 arms), sponsored by CHU de Nantes. Primary endpoint: Treatment success rate. Started Aug 2017; status: terminated.
02
Drugs
spironolactone
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on 2017-001392-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001392-22.